Moreover, immunomodulatory pathways were significantly enriched in both human and murine DLBCL-FRCs, including increased gene expression in inflammatory IFN type I and II responses (Irf8, Ifi27), cytokine and chemokine (Cxcl9, Cxcl10), and MHC class I and II antigen-presentation (HLA genes, B2m and Cd74) pathways (Figure 4E and Supplemental Figure 5, F, G, and M). This evidence concerns the gene CXCL10 and diffuse large B-cell lymphoma.